Enhancing Epidural Ropivacaine Analgesia: The Impact of Dexmedetomidine as an Adjuvant
This study evaluates the effectiveness of dexmedetomidine as an adjunct to epidural ropivacaine (0.75%) in 40 patients undergoing elective lower limb orthopedic surgery. Participants were divided into two groups: a control group receiving ropivacaine alone and a dexmedetomidine group receiving ropivacaine plus dexmedetomidine (1μg/kg). We measured variables such as block onset time, duration of sensory and motor block, postoperative analgesia, and sedation levels. Results showed prolonged analgesia and motor block duration in the dexmedetomidine group, indicating its potential benefits in epidural anesthesia.
Enhancing Epidural Ropivacaine Analgesia: The Impact of Dexmedetomidine as an Adjuvant
E N D
Presentation Transcript
TOPIC EFFECT OF DEXMEDETOMIDINE AS AN ADJUVANT TO EPIDURAL ROPIVACAINE 0.75% DR.Rajaram MD(Final)
NAME : DR.J.RAJARAM COURSE : MD FINAL(ANESTHESIA) CENTER : KILPAUK MEDICAL COLLEGE & HOSPITAL GUIDE : DR.P.S.SHANMUGAM MD.DA PROF & HOD OF ANESTHESIA DEPT OF ANESTHESIA KILPAUK MEDICAL COLLEGE
INTRODUCTION • Hypothesis of this study is to evaluate and compare the effect of added dexmedetomidine to epidural ropivacaine 0.75% • 40 patients under going elective lower limb orthopedic procedures under epidural were selected and divided into two groups of 20 each • Control group- epidural ropivacaine 0.75% 20ml (150mg) • Dex group- epidural ropivacaine 0.75% 20ml (150mg) + Dexmedetomidine 1μg/kg
METHODS • Ethical committee approval • Informed consent • Randomised double blind study • 40 paients under going elective orthopedic procedures were selected • Absolute fasting of 8 hours , without premedication
METHODS INCLUSION CRITERIA EXCLUSION CRITERIA • ASA I & II • BOTH SEXES • AGE BETWEEN 18-70 yrs • ELECTIVE ORTHOPEDIC PROCEDURE • UNDER EPIDURAL ANESTHESIA • WITHOUT COMORBID ILLNESS • ALLERGY TO LOCAL ANESTHETICS • NM DISEASES • USING α2 ANTAGONISTS • WEIGHT MORE THAN 120 kg
CONTD.. • I.V line secured for administration of RL,10ml/kg/hr • Monitors include pulse oximetry, NIBP, ECG • Epidural • Performed with 16G Tuohy needle • Lumbar epidural space • Sitting position • Loss of resistance technique
GROUPS • CONTROL GROUP(N=20) : • Epidural ropivacaine 0.75% 20ml(150mg)+1 ml NS • DXMEDETOMIDINE GROUP(N=20) : • Epidural ropivacaine 0.75% 20ml(150mg)+ Dexmedetomidine 1μg/kg+NS to complete 1ml • 20ml 0.75% injected at the rate of 1ml/3sec • Patients were treated with titrated doses ephedrine 6mg if systolic BP<90mmhg, with atropine 0.6mg if HR<60/min • Patients were sedated on demand basis
VARIABLES • BLOCK ONSET TIME • MAXIMUM DERMATOMAL LEVEL OF ANESTHESIA • DURATION OF SENSORY AND MOTOR BLOCKADE • MOTOR BLOCK INTENSITY-BROMAGE MOTOR SCALE • SENSORY BLOCK-SENSORY SCALE • LEVEL OF SEDATION-RAMSEY SEDATION SCALE • HEMODYNAMICS • DURATION POST OPERATIVE ANALGESIA-VAS SCORE
DEFINITION OF VARIABLES • SENSORY BLOCK ONSET TIME • Time interval between end of anesthetic injection and appearance of cutaneous analgesia in dermatomes T-12,T-10,T-8,T-6 • DURATION OF MOTOR BLOCK • Administration of anesthetic and attainment of grade 0 in Bromage motor scale • DURATION OF ANALGESIA • Administration of anesthetic and disappearance of cutaneous level at each dermatomal level • POST-OP ANALGESIA DURATION • Administration of anesthetic and time of analgesic usage in PACU • SUPPLEMENTAL SEDATION • If patient felt pain or uncomfortable , with pentazocine 0.3mg/kg and or midazolam 0.02mg I.V
STATISTICS • Variables were analyzed with Student ‘t’ test, Chi Square test • Variables like age, sex, weight, height were compared using Levene’s test for equality of variance • Sample size obtained according to previous background study • ‘p’ value less than 0.05 was taken as significant
RESULTS • One patient in control group was excluded for failure of epidural block and need for GA • Distributions of age, weight, height, sex and type of surgery , duration of surgery between groups(p>0.05) • Block onset time T-12,T-10,T-8,T6 between groups-shortened onset time, with less significance(p<0.08) • Regression time is prolonged in dex group(p<0.01) • Maximal level of analgesia assessed after 60mins between groups were T-4 to T-6, without significance
CONTD.. • Duration of analgesia-prolonged in Dex group, level of significance-(p<0.05) • Motor block duration-prolonged in Dex group, level of significance(p<0.05) • Intensity of motor block-increased intensity in dexgroup,without significance(p<0.37) • Supplemental sedation-reduced need in Dex group , level of significance • Patient given supplemental mask O2 if SpO2 <94% • Duration of post-op analgesia-significantly prolonged in Dex group, level of significance (p<0.01)
Contd.. • Need for vasopressors- similar between groups with out much significance(p>0.13) • Occurrence of hypotension with need for vasopressor • Occurrence of bradycardia and need for vagolytic • Hemodynamic stability-stable in both groups without much significance(p<0.06) • Occurrence of other complications like shivering, nausea , RS depression in intra and post-op period –similar between groups • Epidural catheter was used for giving rescue analgesia with 0.2% ropivacaine 10ml (20mg)
ROPIVACAINE • It is a long acting amide local anesthetics • Ropivacaine is ‘S’ isomer of the propyl analogue of mepivacaine and bupivacaine • Similar to bupivacaine ,but with better cadiotoxicity profile, • dissociates from Na+channels more rapidly • Produces less accumulation of Na+channel block • Significantly better sensory-motor differentiation,due to lower lipid solubility than bupivacaine • Has mild intrinsic vasoconstricting properties • unsuitable for infiltration in tissues without collateral blood supply • Reason for longer cutaneous anesthesia
PROPERTIES-ROPIVACAINE • pKa is 8.07 • Protein binding is 94% • Partition co-efficient is 115 • CC:CNS ratio is 5:1 • Potency 4
DISCUSSION • According to result, • There is a synergistic interaction of dex and ropivacaine during epidural administration • Addition of Dex prolongs analgesic and motor blockade duration and post-op analgesia • Decreases the requirement of supplemental sedation • It does not affect onset time
DEXMEDETOMIDINE • Dex is an agonist of α2 adrenergic receptor – agonist where ratio among α2: α1 is 1600:1 • Dex epidural effect is dose dependent and superior than I.V due to its high affinity for α2 adrenergic receptors in spinal cord • Dex first administered epidurally in 1997, combined with 1.5% lignocaine for patients undergoing hystrectomy • 8 times greater selectivity than clonidine towards α2 adrenergic receptor
DEX.. • After epidural administration of Dex , it is rapidly detected in CSF within five mins,however only 22% is absorbed into intra thecal space • Dex inhibition of locus caeruleus results in disinhibition of of NA nuclei and exerts descending inhibitory effect on nociception in spical cord • Anti-nociceptive effect is • Dose dependent • Related to affinity of located α2 in spinal card • Higher lipid solubility • Prolonged analgesic action of LA is due to • Reduced systemic absorbtion caused by local vasoconstriction mediated byα2C in smooth muscle of epidural venous plexus
DEX.. • Sedative effect of Dex, • Mediated by binding to α2A receptors in locus caeruleus • Diminishes release of norepinephrine • During epidural administration cephalad spread into meninges may be responsible for sedation • Dex cause more sensory than motor block duration • 4 times the dose is required for inhibition large ,myelinated Aα fibers when compared to small unmyelinated C fibers • Bradycardia • Is dose dependent • Occurs in epidural if level is higher • Shivering incidence may be reduced with α2 agonists due to central inhibition of thermoregulatory centre
CONCLUSION • DEX has significant synergistic interaction with epidural Ropivacaine in • Prolonging duration of analgesia(p<0.02) • Prolonging duration motor block(p<0.04) • Post-op duration of analgesia(p<0.001) • Ref. braziliascandinavia ,journal